Disclosures for "Comparative Sensitivity of FDG-PET/CT and Contrasted CT in Identifying Biopsy Targets in Neurosarcoidosis"
-
Dr. Morehead has nothing to disclose.
-
Dr. Roy-Hewitson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pharma. Dr. Roy-Hewitson has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pharma.